<DOC>
	<DOCNO>NCT01294631</DOCNO>
	<brief_summary>The purpose study evaluate effect multiple dos hydrochlorothiazide canagliflozin concentration drug blood concentration glucose blood urine healthy adult volunteer .</brief_summary>
	<brief_title>A Pharmacodynamics , Pharmacokinetics , Safety Study Hydrochlorothiazide Canagliflozin Healthy Volunteers</brief_title>
	<detailed_description>This single-center , open-label study 2 study period volunteer study staff know name dos assign study treatment . All volunteer receive treatment . Canagliflozin ( sodium-glucose cotransporter 2-inhibitor ) currently development low blood sugar level patient Type 2 diabetes mellitus ( T2DM ) , hydrochlorothiazide ( HCTZ ) drug indicate treatment patient mild moderate hypertension . During Period 1 , volunteer take canagliflozin 300 mg daily 7 day ( Days 1 7 ) Period 2 , volunteer take HCTZ 25 mg daily 28 day ( Days 1 28 ) , start Day 29 , take canagliflozin 300 mg daily HCTZ 25 mg daily 7 day ( Days 29 35 ) . Period 1 Period 2 separate minimum 14 day .</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Healthy volunteer body mass index ( BMI , measure person 's weight relation height ) 18 30 kg/m2 , inclusive , body weight less 50 kg History current clinically significant medical illness determine Investigator History clinically significant allergy , especially know hypersensitivity intolerance lactose Known allergy canagliflozin excipients formulation canagliflozin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Hydrochlorothiazide</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacodynamic</keyword>
</DOC>